BioSpace News Archive

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends to release its operational highlights and financial results for the quarter ended September 30, 2020 on Tuesday, November 10, 2020,

Canadians have sacrificed much in the months since the pandemic first began. We have come together to protect one another and allow scientists and researchers the time it takes to develop a safe and effective COVID-19 vaccine.

McKesson Corporation (NYSE:MCK) today reported results for the second quarter ended September 30, 2020.

According to the report, the global refurbished medical equipment market was valued at ~US$ 8 Bn in 2018 and is projected to expand at a high CAGR during the forecast period.

XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the rights to future milestone and royalty revenue due to Bioasis Technologies Inc. (TSXV:BTI.V; OTCQB:BIOAF), associated with the advancement of the enzymes being investigated as potential treatments for four different lysosomal storage disorders (LSD) under Bioasis’ strategic alliance with Chiesi Group.

GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced financial results and operating progress for the third quarter ended September 30, 2020.

Humanigen Executes Licensing Agreement for Lenzilumab ™ in COVID-19 with KPM Tech/Telcon RF Pharmaceutical for South Korea and the Philippines Agreement provides Humanigen up to US$20 million in milestones and double-digit royalties on product sales Transaction supports the Humanigen Asia-Pacific regional corporate development strategy BURLINGAME, Calif.--( BUSINESS WIRE )-- Humanigen, Inc . (Nasdaq: HGEN) (“Humanigen”), a clinical

TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the manuscript describing how inhalable liposomal hydroxychloroquine ( TLC19 ) may provide clinical benefit and serve as a potential treatment for COVID-19 has been peer-reviewed and accepted by Clinical and Translational Science (CTS)

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company” or “we”) today announced its third-quarter 2020 financial results.

According to the report, the global genome engineering market was valued at US$ 3,685.4 Mn in 2018 and is anticipated to expand at a CAGR of 10.9% from 2019 to 2027.